FDA Clears Meridian Bioscience's Newborn Cytomegalovirus Test

Nov 30, 2018

NEW YORK (GenomeWeb) – The US Food and Drug Administration announced on Friday it has completed the de novo premarket review and cleared for marketing Meridian Bioscience's cytomegalovirus assay for newborns called the Alethia CMV Assay Test System.

The Alethia brand is the new name for Meridian's molecular test line, which was previously marketed under the Illumigene and Illumipro names.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

The BD Veritor Plus System

Advancing Patient Care and Aiding Diagnosis at the Point of Care

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Molecular Tests Provide a Better Alternative to Stool Culture for GI Cases

Mar

20

Featured Webinar

A New Multiplex Syndromic System For Respiratory Diagnosis And Improved Patient Care

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar

21

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison (Part 2): Best NGS Approaches for Human Transcriptome Sequencing

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar

26

Featured Webinar

Advancing Agricultural Genomics with Low-Cost NGS Genotyping

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Main menu